Health Care·Pharmaceuticals·$35.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | N/A | +6.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.20 | N/A | +6.48% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management appeared cautiously optimistic about the company's performance. They emphasized their commitment to improving efficiency and maintaining market strength.
Management expressed satisfaction with the EPS results despite not providing revenue figures.
They highlighted ongoing efforts to improve operational efficiency.
There was a focus on maintaining strong performance in key markets.
Teva's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 5.05% increase. Investors may be encouraged by the company's focus on operational efficiency and market performance, even though no revenue figures were disclosed. The lack of guidance could lead to some uncertainty among investors going forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WEYERHAEUSER CO REIT
May 6, 2016